Morgan Stanley on Regenxbio Inc. (RGNX): 'we continue to appreciate RGNX’s diversified mid- to late-stage gene therapy pipeline'
Tweet Send to a Friend
Morgan Stanley analyst Judah Frommer reiterated an Overweight rating and $24.00 price target on Regenxbio Inc. (NASDAQ: RGNX).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
